These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21902681)

  • 21. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma.
    Liu S; Ishikawa H; Li FJ; Ma Z; Otsuyama K; Asaoku H; Abroun S; Zheng X; Tsuyama N; Obata M; Kawano MM
    Cancer Res; 2005 Mar; 65(6):2269-76. PubMed ID: 15781640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
    Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
    Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
    Mitsiades CS; Ocio EM; Pandiella A; Maiso P; Gajate C; Garayoa M; Vilanova D; Montero JC; Mitsiades N; McMullan CJ; Munshi NC; Hideshima T; Chauhan D; Aviles P; Otero G; Faircloth G; Mateos MV; Richardson PG; Mollinedo F; San-Miguel JF; Anderson KC
    Cancer Res; 2008 Jul; 68(13):5216-25. PubMed ID: 18593922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
    Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
    Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
    Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model.
    Kanzawa F; Nishio K; Fukuoka K; Sunami T; Saijo N
    Cancer Chemother Pharmacol; 1999; 43(5):353-63. PubMed ID: 10100589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
    Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
    Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma.
    Neri P; Tassone P; Shammas M; Yasui H; Schipani E; Batchu RB; Blotta S; Prabhala R; Catley L; Hamasaki M; Hideshima T; Chauhan D; Jacob GS; Picker D; Venuta S; Anderson KC; Munshi NC
    Leukemia; 2007 Dec; 21(12):2519-26. PubMed ID: 17882285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
    Corso A; Ferretti E; Lazzarino M
    Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Spicamycin derivative].
    Mizumura Y
    Nihon Rinsho; 2006 Feb; 64(2):322-8. PubMed ID: 16454188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reovirus as a viable therapeutic option for the treatment of multiple myeloma.
    Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
    Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways.
    Zheleznyak A; Mixdorf M; Marsala L; Prior J; Yang X; Cui G; Xu B; Fletcher S; Fontana F; Lanza G; Achilefu S
    Theranostics; 2021; 11(16):7735-7754. PubMed ID: 34335961
    [No Abstract]   [Full Text] [Related]  

  • 35. The use of animal models in multiple myeloma.
    Libouban H
    Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
    Yaccoby S; Pearse RN; Johnson CL; Barlogie B; Choi Y; Epstein J
    Br J Haematol; 2002 Feb; 116(2):278-90. PubMed ID: 11841428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRN5500, a novel antitumor agent, induces apoptosis or cell differentiation in HL-60 cells.
    Kawasaki K; Murakami T; Ita M; Sasaki K; Furukawa S
    Cytometry; 2000 Mar; 39(3):211-6. PubMed ID: 10685078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models.
    Takahashi T; Honma Y; Miyake T; Adachi K; Takami S; Okada M; Kumanomidou S; Ikejiri F; Jo Y; Onishi C; Kawakami K; Moriyama I; Inoue M; Tanaka J; Suzumiya J
    Int J Oncol; 2015 Apr; 46(4):1801-9. PubMed ID: 25672400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
    Lath DL; Buckle CH; Evans HR; Fisher M; Down JM; Lawson MA; Chantry AD
    PLoS One; 2018; 13(6):e0199517. PubMed ID: 29924867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor efficacy of lidamycin against human multiple myeloma RPMI 8226 cells and the xenograft in nonobese diabetic/severe combined immunodeficiency mice.
    Zhen Y; Shang B; Liu X; Lin Y; Zhen Y
    J Cancer Res Ther; 2016; 12(1):182-7. PubMed ID: 27072234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.